• <rt id="yksfk"></rt>

    1. <rt id="yksfk"><meter id="yksfk"><p id="yksfk"></p></meter></rt><rp id="yksfk"><meter id="yksfk"></meter></rp>

      <ruby id="yksfk"></ruby>
      1. <source id="yksfk"><nav id="yksfk"><strike id="yksfk"></strike></nav></source>
        1. <tt id="yksfk"><noscript id="yksfk"></noscript></tt>
          <cite id="yksfk"></cite>

          <rt id="yksfk"><nav id="yksfk"><p id="yksfk"></p></nav></rt>

            <rt id="yksfk"><meter id="yksfk"></meter></rt>
          1. Advancing Therapeutics

            Since the founding of Gilead in 1987, we have focused on developing and delivering medications that advance the treatment of life-threatening diseases. The commercial success of our products provides us with the resources to generate new clinical data defining their profiles and supports our development of new therapeutic advancements. As we bring new products into clinical development, our goal remains the same–to discover, develop and commercialize therapeutics that advance patient care.

            Man working in laboratory
            Abstract representation of a timeline

            Pipeline
            Our research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.

            美国一级片